Skip to main content
. 2021 Aug 19;7(10):1–8. doi: 10.1001/jamaoncol.2021.2723

Figure 2. Association of Concomitant 22q11.22 Deletions With Survival Outcome Among Patients With IKZF1 Alterations.

Figure 2.

When all patients in the study were considered (n = 1310), the presence of a 22q11.22 deletion among patients with IKZF1 alterations was associated with significantly worse outcomes. A, Five-year event-free survival: 22q11.22 + IKZF1 double deletion, 43.3%; 22q11.22 wild type (WT) + IKZF1 alteration, 68.5%; and IKZF1 WT, 81.2%. For reference, the 5-year event-free survival rate for all patients was 75.2%. B, Five-year overall survival: 22q11.22 + IKZF1 double deletion, 66.9%; 22q11.22 WT + IKZF1 alteration, 83.9%; and IKZF1 WT, 87.3%. For reference, the 5-year overall survival rate for all patients was 84.3%. Shown are unadjusted hazard ratios; P values are from a log rank test. Overall survival data were not available for all patients.